<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11545">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956642</url>
  </required_header>
  <id_info>
    <org_study_id>EUR-001</org_study_id>
    <nct_id>NCT02956642</nct_id>
  </id_info>
  <brief_title>Study of Unprecedented Glucose Analysis and Results</brief_title>
  <acronym>SUGAR</acronym>
  <official_title>Study of Unprecedented Glucose Analysis and Results: A Randomized Controlled Trial of the Effect of the Livongo Health Diabetes Management Program vs. Standard Care on Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Livongo Health, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a two-arm randomized controlled trial in which participants will receive
      either the Livongo Health system or iHealth glucose meter for measuring their blood glucose.
      The study hypothesizes the use of the Livongo Health system results in a greater improvement
      in A1c compared to standard blood glucose monitoring, as demonstrated by the iHealth
      Bluetooth-enabled glucose meter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in this study will partake in study surveys, daily blood glucose monitor
      measurements, and blood sampling for the duration of their participation. The study intends
      to recruit and randomize 200 participants.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c Levels</measure>
    <time_frame>6 months</time_frame>
    <description>Two HbA1c measures per study participant will be acquired throughout the study duration. In order to compare the changes in HbA1c, the values may be analyzed and separated in regards to subgroup (type 1 or type 2 diabetes), duration of diabetes (days, months, years), and/or HbA1c levels at baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Blood Glucose Monitoring System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive the Livongo Health System to manage diabetes. 100 participants will participate in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Blood Glucose Monitoring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will receive the iHealth Glucose Meter to take blood glucose measurements that will then be compared to participants from the Livongo Health System arm. 100 participants will participate in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Livongo Health System</intervention_name>
    <description>Participants will be asked to use the Livongo Health System to manage their blood glucose.</description>
    <arm_group_label>Blood Glucose Monitoring System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iHealth Glucose Meter</intervention_name>
    <description>Participants will be asked to use the iHealth Glucose Meter to take blood glucose measurements.</description>
    <arm_group_label>Standard Blood Glucose Monitoring</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  People with type 1 or 2 diabetes mellitus on any type of medication

          -  Adults, age 18 years or older

          -  Not using continuous glucose monitoring or an insulin pump

          -  iOS Smartphone with access to data and/or Wi-Fi

        Exclusion Criteria:

          -  Using continuous glucose monitoring during the study period

          -  Using an insulin pump during the study period

          -  Unable or unwilling to switch blood glucose meters to the study meter

          -  Hospitalization for DKA or hypoglycemia in the past 1 month prior to enrollment

          -  Pregnant patients, or intention to become pregnant during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Olgin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hannah Gittleman</last_name>
    <phone>415-502-3046</phone>
    <email>hannah.gittleman@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hannah Gittleman</last_name>
      <phone>415-502-3046</phone>
      <email>hannah.gittleman@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Olgin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 2, 2016</lastchanged_date>
  <firstreceived_date>October 31, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Jeffrey Olgin</investigator_full_name>
    <investigator_title>MD; Chief of the Division of Cardiology; Co-Director of the Heart and Vascular Center; Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
